Pear Therapeutics Inc
NASDAQ:PEAR
Intrinsic Value
Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use softwar... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of PEAR.
Fundamental Analysis
Balance Sheet Decomposition
Pear Therapeutics Inc
| Current Assets | 73m |
| Cash & Short-Term Investments | 59.3m |
| Receivables | 6.9m |
| Other Current Assets | 6.7m |
| Non-Current Assets | 22.2m |
| PP&E | 15m |
| Other Non-Current Assets | 7.2m |
| Current Liabilities | 49.4m |
| Accounts Payable | 3.3m |
| Accrued Liabilities | 16.6m |
| Other Current Liabilities | 29.6m |
| Non-Current Liabilities | 15.1m |
| Other Non-Current Liabilities | 15.1m |
Earnings Waterfall
Pear Therapeutics Inc
|
Revenue
|
12.7m
USD
|
|
Cost of Revenue
|
-7.4m
USD
|
|
Gross Profit
|
5.3m
USD
|
|
Operating Expenses
|
-122.5m
USD
|
|
Operating Income
|
-117.2m
USD
|
|
Other Expenses
|
41.7m
USD
|
|
Net Income
|
-75.5m
USD
|
Free Cash Flow Analysis
Pear Therapeutics Inc
PEAR Profitability Score
Profitability Due Diligence
Pear Therapeutics Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
Pear Therapeutics Inc's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
PEAR Solvency Score
Solvency Due Diligence
Pear Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Pear Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PEAR Price Targets Summary
Pear Therapeutics Inc
Ownership
PEAR Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
PEAR Price
Pear Therapeutics Inc
| Average Annual Return | -21.01% |
| Standard Deviation of Annual Returns |
N/A
|
| Max Drawdown | -100% |
| Market Capitalization | 1.1m USD |
| Shares Outstanding | 138 707 278 |
| Percentage of Shares Shorted | 4.62% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The company is headquartered in Boston, Massachusetts. The company went IPO on 2021-02-02. The firm is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases. Its products include reset, reSET-O and Somryst. Its reset product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for treatment of opioid use disorder (OUD) in combination with buprenorphine. Its Somryst product is the only software-based and guideline-recommended treatment for chronic insomnia. The Company’s pipeline consists of 14 product candidates, including candidates in psychiatry, neurology, and outside of central nervous system therapeutic areas such as gastrointestinal (GI), oncology, and cardiovascular. The company focuses on psychiatric and neurologic conditions, which supports its strategy to commercialize its own products.
You don't have any saved screeners yet
